Archives: Agenda

• How to transition from secondary to primary supplier emissions data and bank the benefit of lower impact products in your supply chain
• Practical approaches for prioritising suppliers, ingredients, and ingredient groups that drive meaningful impact
• Preparing suppliers for data sharing and decarbonisation to drive action beyond reporting
• Case studies on swaps and strategies that have actually reduced supply chain emissions

• The Internet: The New Source of Consumer Truth

Billions of online conversations, reviews, and recipes are reshaping how we understand consumer needs. Learn how AI Palette transforms this unstructured digital chatter into real-time, actionable insights for CPG innovation.

• AI Transformation: From Traditional Analytics to LLMs and Agentic AI

The evolution of AI is redefining how insights are generated, moving from traditional analytics to autonomous, reasoning-driven systems that can interpret culture, context, and emotion at scale.

• Empowering CPG Brands to Discover, Launch, and Grow with Proprietary AI

AI Palette’s patented and proprietary technology helps brands identify emerging trends, optimize product concepts, and accelerate go-to-market success – all powered by a deep understanding of consumer data and ingredient innovation.

• The Future of Insights: Always-On, Adaptive, and Predictive

We’re entering an era where insights aren’t static reports but living, evolving systems, continuously learning from the world’s conversations to guide faster, smarter product decisions.

• Identifying and addressing key barriers that limit timely and representative recruitment.
• Improving collaboration between sites, sponsors and patient advocacy groups to expand referral pathways.
• Enhancing patient trust and understanding through clear, accessible communication strategies.
• Leveraging AI tools to support more accurate pre-screening, eligibility matching and outreach.

• Reimagining responsibilities across clinical trial functions in an AI- and automation-driven environment
• Evolving from task-based roles to strategic, insight-driven contributors across operations and data functions
• Redefining entry-level roles as technology reshapes foundational skills, expectations, and career pathways
• Identifying the new capabilities required to ensure technology enhances, not replaces the expertise of clinical trial professionals

Robust, well supported site infrastructure is the foundation of efficient clinical trial delivery across the UK and Ireland. This session will examine how workforce, facilities, digital systems and governance structures at NHS and HSE sites can be optimised to reduce operational burden and increase throughput of high quality studies. Panellists will share practical strategies for investing in and partnering with sites to strengthen research infrastructure, streamline processes, and enable sustainable growth in commercial and academic trial activity.

• Assessing current site infrastructure: workforce, facilities, governance and digital capabilities in NHS/HSE settings.
• Targeted investments and partnerships that meaningfully strengthen site capacity and trial readiness.
• Aligning sponsor/CRO expectations and processes with real site infrastructure constraints.
• Building scalable, resilient site infrastructure that supports long term growth in UK & Irish clinical research.

• Implementing MHRA and HRA expectations for innovative oncology trial designs (platform, basket and adaptive studies)
• Integrating biomarkers, companion diagnostics and expedited pathways within the UK regulatory framework (e.g. ILAP, EAMS)
• Operationalising UK‑specific approvals: interplay of MHRA, HRA/REC, UK GDPR and local R&D for oncology studies
• Positioning UK oncology trials in a post‑Brexit environment: alignment with EU/ICH standards and leveraging UK flexibility